Laboratory diagnosis of human papillomavirus infection

Current Problems in Dermatology (Switzerland)

Volumn 45, Issue , 2014, Pages 166-174

  Ikenberg, Hans ^a  

^a MVZ CytoMol   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; VIRUS DNA;

ANTIBODY DETECTION; ARTICLE; CANCER PREVENTION; CANCER RISK; CHEMOLUMINESCENCE; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; GENE AMPLIFICATION; GENOTYPE; HIGH RISK POPULATION; HIV RAPID TEST; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LABORATORY DIAGNOSIS; NUCLEIC ACID ANALYSIS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RIBONUCLEIC ACID TESTING; SENSITIVITY AND SPECIFICITY; SIGNAL AMPLIFICATION ASSAY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CLINICAL LABORATORY TECHNIQUES; DNA, VIRAL; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84922480829     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000356515     Document Type: Article

References (43)

1. Cardoso JC, Calonje E: Cutaneous manifestations of human papillomaviruses: A review. Acta Dermatovenerol Alp Panonica Adriat 2011; 20: 145-154
2. Hengge UR: Role of viruses in the development of squamous cell cancer and melanoma. Adv Exp Med Biol 2008; 624: 179-186
3. Schiffman M, Wentzensen N, et al: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103: 368-383
4. Saslow D, Runowicz CD, et al: American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-362
5. Katki HA, Kinney WK, et al: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A populationbased study in routine clinical practice. Lancet Oncol 2011; 12: 663-672
6. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM: Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-297
7. Josefsson AM, Magnusson PK, et al: Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested casecontrol study. Lancet 2000; 355: 2189-2193
8. Snijders PJ, van den Brule AJ, et al: The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6
9. Hesselink AT, van den Brule AJ, et al: Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer 2004; 102: 11-18
10. Wang SS, Schiffman M, et al: Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10,000 women in Costa Rica. Br J Cancer 2003; 89: 1248-1254
11. Lorincz AT, Smith JS: Sexually transmissible viral pathogens: human papillomaviruses and herpes simplex viruses; in Lorincz AT, Smith JS (eds): Nucleic Acid Testing for Human Disease. Boca Raton, Taylor Francis CRC Press, 2006, pp 244-273
12. Castle PE, Wheeler CM, et al: Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122: 238-245
13. Quint WG, Pagliusi SR, et al: Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 2006; 44: 571-579
14. Castle PE, Cox JT, et al: An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol 2008; 111: 847-856
15. Castle PE, Gutierrez EC, et al: Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol 2011; 49: 3029-3032
16. Youens KE, Hosler GA, et al: Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn 2011; 13: 160-166
17. Castle PE, Solomon D, et al: Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008; 46: 2595-2604
18. Goldstone SE, Lowe B, et al: Evaluation of the hybrid capture 2 assay for detecting anal high-grade dysplasia. Int J Cancer 2012; 131: 1641-1648
19. Kinney W, Stoler MH, et al: Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010; 134: 193-199
20. Quigley NB, Potter NT, et al: Rate of detection of high-risk HPV with two assays in women >/=30 years of age. J Clin Virol 2011; 52: 23-27
21. Kleter B, van Doorn LJ, et al: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 2508-2517
22. Jacobs MV, Snijders PJ, et al: A general primer GP5/GP6()-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791-795
23. Gravitt PE, Peyton CL, et al: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-361
24. Karlsen F, Kalantari M, et al: Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996; 34: 2095-2100
25. Qu W, Jiang G, et al: PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5/GP6 primer systems. J Clin Microbiol 1997; 35: 1304-1310
26. Wright TC Jr, Cox JT, et al: 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-2129
27. Wright TC Jr, Massad LS, et al: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-355
28. Rebolj M, Bonde J, et al: Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ 2011; 342:d2757
29. Schiffman M, Khan MJ, et al: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 147-150
30. Meijer CJ, Berkhof J, et al: Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520
31. Stoler MH, Wright TC Jr, et al: High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135: 468-475
32. Castle PE, Stoler MH, et al: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-890
33. Heideman DA, Hesselink AT, et al: Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011; 49: 3983-3985
34. Cuzick J, Ambroisine L, et al: Performance of the Abbott real-time high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010; 82: 1186-1191
35. Hesselink AT, Heideman DA, et al: Comparison of the clinical performance of Papillocheck human papillomavirus detection with that of the GP5/6-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol 2010; 48: 797-801
36. Khan MJ, Castle PE, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079
37. Castle PE, Rodriguez AC, et al: Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009; 339:b2569
38. Wheeler CM, Hunt WC, et al: Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006; 194: 1291-1299
39. Molden T, Kraus I, et al: Comparison of human papillomavirus messenger RNA and DNA detection: A cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14: 367-372
40. Castle PE, Dockter J, et al: A cross-sectional study of a prototype carcinogenic human papillomavirus E6/ E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007; 13: 2599-2605
41. Szarewski A, Ambroisine L, et al: Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-3042
42. Schmitt M, Dalstein V, et al: Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res 2010; 70: 249-256
43. Burger EA, Kornor H, et al: HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecol Oncol 2011; 120: 430-438.